Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting
Status:
Withdrawn
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Chemotherapy-induced nausea and vomiting (CINV) adversely affects patients' quality of life
and may affect patients' treatment decisions. The emetogenicity of the chemotherapy
administered and specific patient characteristics such as female gender, age, and history of
low alcohol intake can increase a patients' risk for CINV.
GERSC is a new, subcutaneously (SC) administered polymeric formulation of Granisetron that
was developed to provide slow, controlled, and sustained release of Granisetron to prevent
both acute and delayed CINV associated with moderately emetic chemotherapy (MEC) and highly
emetic chemotherapy (HEC)